Articles
慢性乙型肝炎联合抗病毒治疗研究进展
Abstract
Keywords
References
WORLD HEALTH ORGANIZATION. Global progress report on HIV, viral hepatitis and sexually transmitted infections[R]. Geneva: WHO, 2021.
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12): 1309-1331. Chinese Society of Hepatology, Chinese Society of Infectious Diseases. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. Chin J Hepatol, 2022, 30(12): 1309-1331.
TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Upda-te on prevention, diagnosis, and treatment of chronic hep-atitis B: AASLD 2018 hepatitis B guidance[J]. Hepatolog-y, 2018, 67(4): 1560-1599.
EUROPEAN ASSOCIATION FOR THE STUDY OF THELIVER. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 20-17, 67(2): 370-398.
YUEN MF, CHEN DS, DUSHEIKO GM, et al. HepatitisB virus infection[J]. Nat Rev Dis Primers, 2018, 4: 18035.
YUEN MF, LIM SG, PLESNIAK R, et al. Efficacy and sa132亚洲临床医学杂志·第09卷·第11期·2026年11月fety of bepirovirsen in chronic hepatitis B infection[J]. NEngl J Med, 2022, 387(21): 1957-1968.
CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafena-mide versus tenofovir disoproxil fumarate for the treatme-nt of HBeAg-positive chronic hepatitis B virus infection:a randomised, double-blind, phase 3, non-inferiority trial[-J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195.
BUTI M, GANE E, SETO WK, et al. Tenofovir alafenami-de versus tenofovir disoproxil fumarate for the treatmentof patients with HBeAg-negative chronic hepatitis B virusinfection: a randomised, double-blind, phase 3, non-inferi-ority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206.
XIE C, LIN B, MO Z, et al. Peginterferon α-2b enhanceshepatitis B surface antigen loss in nucleos(t)ide analogue--suppressed low hepatitis B surface antigen chronic hepati-tis B patients: Everest Study in China[J]. Clin Gastroenter-ol Hepatol, 2026. DOI: 10.1016/j.cgh.2026.01.029. Epubahead of print. PMID: 41638418.
HOU J, ZHANG W, XIE Q, et al. Xalnesiran with or wit-hout an immunomodulator in chronic hepatitis B[J]. N Engl J Med, 2024, 391(22): 2098-2109.
CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellularcarcinoma across a biological gradient of serum hepatitisB virus DNA level[J]. JAMA, 2006, 295(1): 65-73.
EUROPEAN ASSOCIATION FOR THE STUDY OF TH-E LIVER. EASL Clinical Practice Guidelines on the ma-nagement of hepatitis B virus infection[J]. J Hepatol, 20-25, 83: 502-583.
ANDERSON RT, CHOI HSJ, LENZ O, et al. Associationbetween seroclearance of hepatitis B surface antigen andlong-term clinical outcomes of patients with chronic hep-atitis B virus infection: systematic review and meta-anal-ysis[J]. Clin Gastroenterol Hepatol, 2021, 19(3): 463-47-2.
MARCELLIN P, HEATHCOTE EJ, BUTI M, et al. Teno-fovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med, 2008, 359(23): 244-2-2455.
MARCELLIN P, GANE E, BUTI M, et al. Regression ofcirrhosis during treatment with tenofovir disoproxil fum-arate for chronic hepatitis B: a 5-year open-label follow--up study[J]. Lancet, 2013, 381(9865): 468-475.
AGARWAL K, BRUNETTO M, SETO WK, et al. 96 we-eks treatment of tenofovir alafenamide vs. tenofovir dis-oproxil fumarate for hepatitis B virus infection[J]. J He-patol, 2018, 68(4): 672-681.
刘智泓, 金清龙, 张跃新, 等. 延长或转换为艾米替诺福韦治疗在慢性乙型肝炎患者中的疗效评估:一项Ⅲ期随机对照研究[J]. 中华肝脏病杂志, 2024, 32(10): 883-892. LIU ZH, JIN QL, ZHANG YX, et al. Efficacy evaluation of extended or switch to tenofovir amibufenamide treatment in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study[J]. Chin J Hepatol, 2024, 32(10): 883-892.
CHOI WM, YIP TC, WONG GL, et al. Hepatocellular carcinoma risk in patients with chronic hepatitis B receivin-g tenofovir- vs. entecavir-based regimens: individual pa-tient data meta-analysis[J]. J Hepatol, 2023, 78(3): 534--542.
YUEN MF, LOCARNINI S, LIM TH, et al. Combinationtreatments including the small-interfering RNA JNJ-3989induce rapid and sometimes prolonged viral responses inpatients with CHB[J]. J Hepatol, 2022, 77(5): 1287-1298.
LEE SW, KWON JH, LEE HL, et al. Comparison of ten-ofovir and entecavir on the risk of hepatocellular carcino-ma and mortality in treatment-naïve patients with chronichepatitis B in Korea: a large-scale, propensity score anal-ysis[J]. Gut, 2020, 69(7): 1301-1308.
HSU YC, WONG GL, CHEN CH, et al. Tenofovir versusentecavir for hepatocellular carcinoma prevention in aninternational consortium of chronic hepatitis B[J]. Am JGastroenterol, 2020, 115(2): 271-280.
ZHAO Q, LIU H, TANG L, et al. Mechanism of interfer-on alpha therapy for chronic hepatitis B and potential ap-proaches to improve its therapeutic efficacy[J]. AntiviralRes, 2024, 221: 105782.
LAU GK, PIRATVISUTH T, LUO KX, et al. Peginterfer-on Alfa-2a, lamivudine, and the combination for HBeAg--positive chronic hepatitis B[J]. N Engl J Med, 2005, 35-2(26): 2682-2695.
MARCELLIN P, LAU GK, BONINO F, et al. Peginterfer-on alfa-2a alone, lamivudine alone, and the two in comb-ination in patients with HBeAg-negative chronic hepatitisB[J]. N Engl J Med, 2004, 351(12): 1206-1217.
NING Q, HAN M, SUN Y, et al. Switching from entecav-ir to PegIFN alpha-2a in patients with HBeAg-positivechronic hepatitis B: a randomised open-label trial (OSSTtrial)[J]. J Hepatol, 2014, 61(4): 777-784.
MARCELLIN P, AHN SH, MA X, et al. Combination oftenofovir disoproxil fumarate and peginterferon alpha-2aincreases loss of hepatitis B surface antigen in patients133亚洲临床医学杂志·第09卷·第11期·2026年11月with chronic hepatitis B[J]. Gastroenterology, 2016, 150-(1): 134-144.
王佳露, 席德扬, 颜学兵, 等. 聚乙二醇干扰素α-2b治疗HBeAg阴性慢性乙型肝炎患者实现HBsAg清除的预测因素及列线图构建[J]. 临床肝胆病杂志, 2023, 39(12): 2809-2816. WANG JL, XI DY, YAN XB, et al. Predictors of HBsAg clearance and nomogram construction in HBeAg-negative chronic hepatitis B patients treated with pegylated interferon alpha-2b[J]. J Clin Hepatol, 2023, 39(12): 2809-2816.
胡晓宇, 季佳, 李兰娟. 核苷(酸)类似物联合聚乙二醇干扰素治疗慢性乙型肝炎实现临床治愈的影响因素分析[J]. 中华临床感染病杂志, 2024, 17(2): 126-132. HU XY, JI J, LI LJ. Analysis of influencing factors for functional cure in chronic hepatitis B patients treated with nucleos(t)ide analogues combined with pegylated interferon[J]. Chin J Clin Infect Dis, 2024, 17(2): 126-132.
周召, 阿卜杜热西提·阿卜来提, 顾智强, 等. 尽早启动抗病毒治疗降低慢性HBV感染者肝细胞癌发生风险[J]. 临床肝胆病杂志, 2023, 39(1): 31-36. ZHOU Z, ABDUREXIT A, GU ZQ, et al. Early initiation of antiviral therapy reduces hepatocellular carcinoma risk in patients with chronic HBV infection[J]. J Clin Hepatol, 2023, 39(1): 31-36.
YUEN MF, LIM YS, YOON KT, et al. VIR-2218 (elebsi-ran) plus pegylated interferon-alfa-2a in participants wit-h chronic hepatitis B virus infection: a phase 2 study[J].Lancet Gastroenterol Hepatol, 2024, 9(12): 1121-1132.
GOYAL A, MURRAY JM. Cost-effectiveness of peg-int-erferon, interferon and oral nucleoside analogues in thetreatment of chronic hepatitis B and D infections in Chi-na[J]. Clin Drug Investig, 2016, 36(8): 637-648. DOI: 10.1007/s40261-016-0409-8.
DAI Z, WONG IO, XIE C, et al. Cost-effectiveness anal-ysis of first-line treatment for chronic hepatitis B in Chi-na[J]. Clin Microbiol Infect, 2022, 28(2): 300.e1-300.e8.DOI: 10.1016/j.cmi.2021.06.023.134

